ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CLDX
NEOG (47) NTLA (25) QDEL (21) ORKA (53) ⌘ Pro Terminal →

Celldex Therapeutics Inc. (CLDX) — RQD Stock Rating Cockpit

$29.04 -3.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.80

Celldex Therapeutics Inc. (CLDX) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.36B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLDX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Celldex Therapeutics Inc. (NASDAQ: CLDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $29.04 (-3.52% 1D, market cap $2.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CLDX ranks #820 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLDX compare to NEOG and NTLA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), CLDX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 87.1%, and ROIC of -35.0%. By comparison, NEOG (Neogen Corporation) holds a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, CLDX leads on earnings multiple (N/A) while NEOG leads on capital efficiency (-0.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLDX?
▼

Per CLDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000744218), Celldex Therapeutics Inc. generated $1.5M in revenue (-78.0% YoY), -$258.8M in net income, and -$213.7M in free cash flow against $583.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $28.80 (-0.82%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (9)Whales (6)SEC (8)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.1% Base Target
$47 Bull$25 Base$20 Bear
📬 FREE CLDX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLDX)Realized 20D OHLCV Swing Band: ±8.7%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY CLDX SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 87.1% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 20.25 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
21
Grade E$28.25+7.2% Next Q
Q2 (-2Q)
24
Grade E$30.29-0.5% Next Q
Q3 (-1Q)
26
Grade E$30.15-3.7% Next Q
Current
29
Grade E$29.04-9.8% Hist 90D α
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLDX currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($33.64) and Max Pain ($30.49) forces dealer call-delta covering toward $47.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
45.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
20.25>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE30% OF RANGE
L: $22$29.04H: $45
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 11 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CLDX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-35.0% ROIC with 87.1% gross margin and -9.10% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 20.25 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (20)

9/40 institutional & smart-money positioning score with 3/20 macro alignment.

Bull Case: Why Buyers Like CLDX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLDX)

  • ✓Walkthrough of CLDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.38%📐 HORIZONTAL RANGE
2026-11-03O $29.89H $30.10L $29.04C $29.04VOL 870.8K
RES: $42.39SUP: $26.31SMA50: $33.64SMA200: $32.69
$46.44$41.06$35.69$30.32$24.94RES $42.39SUP $26.31$29.042026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLDX Butterfly Map → + Track CLDX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -78.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLDX)

Health Care Rank #820 of 1015 ⚔️ NEOG vs CLDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLDX vs. NEOG, NTLA, QDEL, ORKA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Celldex Therapeutics Inc. (CLDX) ranks #820 by composite RQD confidence (29/100, grade E) and #225 by equity capitalization ($2.36B). Within this direct 5-issuer industry benchmark cohort, CLDX leads on earnings valuation at N/A trailing P/E, while NEOG leads on capital efficiency and profitability with -0.6% ROIC and 46.9% gross margin. ORKA currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with CLDX at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLDX ACTIVE
Celldex Therapeutics Inc.
E 29/100 — 87.1% -35.0% -3.52% $2.36B Benchmark Subject
NEOG
Neogen Corporation
D 47/100 — 46.9% -0.6% 0.00% $2.58B /neog-vs-cldx →
NTLA
Intellia Therapeutics Inc.
E 25/100 — — -35.0% -6.50% $1.75B /ntla-vs-cldx →
QDEL
QuidelOrtho Corporation
E 21/100 — — -35.0% +5.89% $908.6M /qdel-vs-cldx →
ORKA
Oruka Therapeutics Inc.
D+ 53/100 — — -18.8% -1.49% $6.41B /orka-vs-cldx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000744218 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Celldex Therapeutics Inc. (CLDX) reported GAAP revenue of $1.5M (-78.0% vs. FY2024 revenue of $7.0M , and -77.6% cumulative change since FY2023) , GAAP net income of -$258.8M, operating cash flow of -$210.9M, and free cash flow of -$213.7M (-33.8% YoY). On the balance sheet, CLDX closed FY2025 with $583.0M in total assets against $0 in total debt (Altman Z-Score: 20.25, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.5M -$258.8M -$210.9M -$213.7M $583.0M —
FY2024 (FY) 2024-12-31 $7.0M -$157.9M -$157.8M -$159.7M $792.3M —
FY2023 (FY) 2023-12-31 $6.9M -$141.4M -$107.3M -$107.3M — —

3. CLDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Celldex Therapeutics Inc. (NASDAQ: CLDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $29.04 (-3.52% 1D, market cap $2.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CLDX ranks #820 in composite RQD confidence.

How does CLDX compare to NEOG and NTLA in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), CLDX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 87.1%, and ROIC of -35.0%. By comparison, NEOG (Neogen Corporation) holds a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, CLDX leads on earnings multiple (N/A) while NEOG leads on capital efficiency (-0.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLDX?

Per CLDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000744218), Celldex Therapeutics Inc. generated $1.5M in revenue (-78.0% YoY), -$258.8M in net income, and -$213.7M in free cash flow against $583.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLDX trading relative to its 50-day, 200-day, and 52-week technical levels?

CLDX last traded at $29.04 (-3.52% on volume of 956,143 shares), positioning the stock -13.67% below its 50-day simple moving average ($33.64) and -11.17% below its 200-day simple moving average ($32.69). Across its 52-week range of $22.10 to $45.14, CLDX sits at the 30.1% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.7% ($26.51 to $31.57).

Direct Sub-Reports: CLDX RQD Cockpit CLDX 12M Forecast CLDX Earnings & Move CLDX Dividends & DRIP CLDX Insiders & 13F CLDX Whale Options CLDX Profit Sankey CLDX News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

CLDX — Celldex Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Celldex Therapeutics Inc. (CLDX) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $29.04 (-3.52% 1D, market capitalization $2.36B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 87.1%, operating margin of -60.0%, and free cash flow yield of -9.10%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 20.25, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Celldex Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry,. Reported revenue was $1.5M in FY 2025, $7.0M in FY 2024, and $6.9M in FY 2023, . — for further detail on how the company monetizes its offerings.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Celldex Therapeutics Inc. (CLDX) reported $1.5M in annual revenue (up from $7.0M in FY2024, -78.0% YoY) and -$258.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.9M revenue, -$141.4M net income) through FY2025, CLDX scaled operating cash flow to -$210.9M and free cash flow to -$213.7M, backed by $583.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.10% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $22.10 – $45.14 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), CLDX carries a macro regime beta of 1.00 and gross margin of 87.1%.

  • Key Question #1: Can CLDX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.5M and free cash flow of -$213.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CLDX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Celldex Therapeutics Inc. (CLDX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLDX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLDX Bull vs. Bear Conversation Board — What's Your Call at $29.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLDX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CLDX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $39.13 (+30.0%)
📌 Pinned Debate

Gross margin of 87.1% and a CATALYST-flagged news item indicate strong unit economics and potential upside if operating losses narrow.

Here is why I am bullish on CLDX here at $30.10: Gross margin of 87.1% and a CATALYST-flagged news item indicate strong unit economics and potential upside if operating losses narrow.. Compare CLDX's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: In Vitro & In Vivo Diagnostic Substances. As long as cash conversion holds up, dips toward $28.59 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — CLDX's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $25.59 (-15.0%)
Spot @ $30.10

Free cash flow of -$213.7M against $28.9M of cash and an RQD score of 28 (Grade E) point to significant forensic and liquidity risk.

Free cash flow of -$213.7M against $28.9M of cash and an RQD score of 28 (Grade E) point to significant forensic and liquidity risk.. Look at the math on CLDX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $26.49 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%